Calidi Biotherapeutics, Inc. (CLDI)

Calidi Biotherapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-26.29	-29.22	-25.43	-10.93	-7.94
Depreciation & Amortization	1.51	1.26	0.26	0.16	0.11
Other Amortization	-0.24	0.43	0.12	0.56	0.08
Loss (Gain) From Sale of Assets	0.01	0.01	-	-	-
Asset Writedown & Restructuring Costs	-	-	-	0.17	-
Stock-Based Compensation	3.52	4.81	4.52	1.33	0.97
Other Operating Activities	-1.5	1.97	3.74	-0.15	1.01
Change in Accounts Payable	2.02	-6.17	1.62	-0.24	0.29
Change in Other Net Operating Assets	1.52	-0.07	1.95	1.34	0.65
Operating Cash Flow	-19.46	-26.98	-13.21	-7.77	-4.83
Capital Expenditures	-0.08	-0.59	-0.43	-0.21	-0.35
Cash Acquisitions	-	0.01	-	-	-
Other Investing Activities	0.04	0.1	-0.07	-0.01	-0.04
Investing Cash Flow	-0.05	-0.48	-0.49	-0.22	-0.39
Short-Term Debt Issued	-	3.25	1.5	1.5	0.6
Long-Term Debt Issued	-	-	-	0.38	1.44
Total Debt Issued	5.8	3.25	1.5	1.88	2.04
Short-Term Debt Repaid	-	-1.3	-0.04	-0.1	-0.1
Long-Term Debt Repaid	-	-1.05	-0.08	-0.03	-0.06
Total Debt Repaid	-4.16	-2.35	-0.12	-0.13	-0.16
Net Debt Issued (Repaid)	1.64	0.9	1.38	1.75	1.88
Issuance of Common Stock	9.24	0.28	0.11	0.14	3
Other Financing Activities	0.42	3.37	10.59	7.93	-0
Financing Cash Flow	11.3	29.04	12.09	9.81	4.7
Foreign Exchange Rate Adjustments	-0.05	-0.01	-0.03	-0	0
Net Cash Flow	-8.25	1.58	-1.65	1.82	-0.51
Free Cash Flow	-19.54	-27.57	-13.64	-7.98	-5.18
Free Cash Flow Margin	-	-	-30315.56%	-1777.28%	-
Free Cash Flow Per Share	-3.85	-16.32	-16.04	-4.04	-3.02
Cash Interest Paid	0.37	0.4	0.04	0.05	0.02
Cash Income Tax Paid	-	0.01	0.01	0.01	0
Levered Free Cash Flow	-13.53	-43.96	6.74	12.15	-
Unlevered Free Cash Flow	-12.68	-43.72	6.72	11.97	-
Change in Net Working Capital	-2	31.08	-16.82	-16.7	-

Source: S&P Capital IQ. Standard template. Financial Sources.